Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Bolt Biotherapeutics (BOLT) over the last 5 years, with Q3 2025 value amounting to 0.76%.

  • Bolt Biotherapeutics' Return on Capital Employed rose 100.0% to 0.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76%, marking a year-over-year increase of 100.0%. This contributed to the annual value of 0.64% for FY2024, which is 2000.0% down from last year.
  • As of Q3 2025, Bolt Biotherapeutics' Return on Capital Employed stood at 0.76%, which was up 100.0% from 0.8% recorded in Q2 2025.
  • Bolt Biotherapeutics' Return on Capital Employed's 5-year high stood at 0.2% during Q2 2021, with a 5-year trough of 0.86% in Q1 2025.
  • Over the past 5 years, Bolt Biotherapeutics' median Return on Capital Employed value was 0.46% (recorded in 2023), while the average stood at 0.52%.
  • As far as peak fluctuations go, Bolt Biotherapeutics' Return on Capital Employed plummeted by -3100bps in 2024, and later surged by 100bps in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Return on Capital Employed stood at 0.3% in 2021, then plummeted by -39bps to 0.42% in 2022, then decreased by -22bps to 0.52% in 2023, then crashed by -59bps to 0.82% in 2024, then rose by 8bps to 0.76% in 2025.
  • Its last three reported values are 0.76% in Q3 2025, 0.8% for Q2 2025, and 0.86% during Q1 2025.